Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. August 2018 08:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review

April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...
09. August 2018 16:05 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights

Gimoti™ NDA submitted to FDA on June 1st; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif., Aug. 09,...
04. Juni 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Announces FDA Submission of New Drug Application for Gimoti™

SOLANA BEACH, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
14. Mai 2018 06:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2018 Results and Highlights

NDA submission for Gimoti™ on track for second quarter of 2018Announced discovery of sex-based pharmacokinetic differences for GimotiWaiver of the PDUFA fee for Gimoti NDA granted by FDACash runway...
10. Mai 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

SOLANA BEACH, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
30. April 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Granted First Gender Specific Patent for Gimoti™

SOLANA BEACH, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
26. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

SOLANA BEACH, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
07. März 2018 16:05 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ doseAnnounced discovery of sex-based pharmacokinetic differences for Gimoti™Met with FDA...
06. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

SOLANA BEACH, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
05. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

SOLANA BEACH, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...

Vorherige Seite